MedPath

TO STUDY ROLE OF EPITHELIAL MESENCHYMAL TRANSITION MARKER IN ORAL CANCER

Not Applicable
Conditions
Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Registration Number
CTRI/2021/08/035485
Lead Sponsor
AIIMS RISHIKESH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age â?? 18 to 70 years.

2.ECOG-PS 0-2.

3.Biopsy proved Oral cavity squamous cell carcinoma.

4.Treated with upfront surgery with curative intent.

5.Details of one-year regular follow-up available.

Exclusion Criteria

1.Recurrent cancer.

2.Synchronous / metachronous cancer.

3.Prior anticancer treatment (Surgery, chemotherapy, radiotherapy, immunotherapy).

4.Patient not willing to participate in the study.

5.Complete required information not available.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To estimate the Prevalence of expression of Epithelial Mesenchymal Transition markers E cadherin N cadherin Vimentin ZEB1 in oral cavity squamous cell cancersTimepoint: TWO YEARS JANUARY 01 2020 TO DECEMBER 31 2022
Secondary Outcome Measures
NameTimeMethod
1.To study the correlation of Epithelial-Mesenchymal Transition markers expression with the disease stage and histopathological factors. <br/ ><br>2.To determine the role of Epithelial-Mesenchymal Transition markers expression in predicting 1-year locoregional control rates <br/ ><br>Timepoint: TWO YEARS JANUARY 01 2020 TO DECEMBER 31 2022
© Copyright 2025. All Rights Reserved by MedPath